People often ask which one is better, clomiphene or enclomiphene, as if they were choosing between two competing brands. That’s not quite the right question. The two are related the way a whole fruit is related to one of its segments. Once that relationship is clear, the rest of the comparison gets a lot easier to think through.
A quick note before anything else: both of these are prescription medicines, using either one for testosterone in men is off-label, and the decision between them belongs to a licensed clinician working from actual bloodwork. Nothing here is a protocol to follow on your own.
One molecule, two names
Clomiphene citrate isn’t a single, pure compound. It’s a mix of two mirror-image molecules called isomers: enclomiphene and zuclomiphene. Enclomiphene is the more active of the pair and leaves the body fairly quickly. Zuclomiphene sticks around much longer and carries more estrogen-like activity.
So when someone asks about “enclomiphene,” they’re really asking about one half of clomiphene, isolated and given on its own. Both work the same way: as a selective estrogen receptor modulator, each blocks estrogen signaling in the hypothalamus, which prompts the brain to release more gonadotropin-releasing hormone, which in turn tells the pituitary to raise LH and FSH, and testosterone follows [5]. The biology is shared because, quite literally, one is a piece of the other.
The approval story isn’t what people assume
This is where the two genuinely part ways, and where the usual rivalry framing gets it backwards.
Clomiphene citrate is FDA-approved. It’s been on the market for decades under the name Clomid, approved for ovulatory dysfunction in women trying to conceive [1]. That approval is real, but it’s narrow. It covers female fertility only. There’s no approved use in men anywhere on the label, so testosterone treatment with clomiphene is off-label [5].
Enclomiphene took a different road. It was developed specifically as a men’s testosterone drug, under the name Androxal, and made it into late-stage trials for secondary hypogonadism. The FDA didn’t approve it. In 2015 the agency sent a complete response letter asking for more studies, that additional work never got finished, and development stopped. There is no FDA-approved enclomiphene product on the market today. Where it’s used, it’s compounded, off-label, same regulatory bucket as men’s use of clomiphene.
So the honest version is this: clomiphene is an approved drug being used off-label in men. Enclomiphene is an unapproved compound being used off-label in men. Neither one has a men’s-health product with FDA approval sitting on a pharmacy shelf, and any claim that enclomiphene is the “approved” option has the facts turned around.
What the evidence actually shows
Because both compounds share a mechanism, the strongest research treats them as one class rather than pitting them against each other, and that’s exactly the approach the best available evidence takes.
A 2025 systematic review and meta-analysis in Archives of Endocrinology and Metabolism pooled randomized trials of clomiphene and enclomiphene together against placebo, testosterone gel, and hCG. Combined, SERM therapy raised total testosterone by about 274 ng/dL versus placebo (95% CI roughly 192 to 356 ng/dL), with LH and FSH rising as expected [4]. Sperm parameters looked better with SERM therapy than with testosterone gel [4], which fits the broader picture: men trying to protect fertility are usually steered away from straight testosterone replacement.
The fact that this meta-analysis pools the two together says something on its own. For the outcome most men actually care about, raising testosterone while keeping fertility intact, the data treats them as one class, not two distinct products. Smaller trials of clomiphene alone point the same direction. A 2018 placebo-controlled study of 78 men found significant increases in total and free testosterone, plus LH and FSH, at 50 mg of clomiphene [2]. A separate randomized study confirmed that clomiphene raises testosterone by working on the pituitary, not the adrenal glands, which is the mechanism you’d expect [3].
What’s missing so far is a large, dedicated head-to-head trial that shows one isomer formulation beating the other on real outcomes. The theory behind enclomiphene, that stripping out the longer-lasting zuclomiphene might reduce estrogen-related effects, is a reasonable idea grounded in pharmacology. It’s a plausible mechanism, not a proven advantage, and that distinction matters.
The side effect both share
Both compounds carry the same warning worth taking seriously: visual disturbances, including blurred vision and flickering or shimmering spots, sometimes called scintillating scotomata. Standard guidance is to stop the medication and get an eye exam if these appear [5]. Because enclomiphene works through the same SERM mechanism, it deserves the same attention, even though the direct evidence base for it is thinner. This is one reason monitoring matters no matter which one is used.
Matching the evidence to what someone actually wants
Once the chemistry and the regulatory picture are sorted out, the real-world question gets smaller and more honest than “which one wins.”
If the goal is raising testosterone while protecting fertility, the class-level evidence applies to both, and it’s meaningful [4]. Choosing between the full mixture and the isolated isomer, in that case, is a judgment call a prescriber makes based on how someone responds, how they tolerate it, and their side-effect profile. It isn’t a verdict the published evidence hands down in advance.
If someone is drawn to the idea that the isolated isomer might mean fewer estrogen-related effects, that’s a fair thing to bring up with a clinician, as long as it’s treated as a plausible idea rather than a settled fact. And if the decision comes down to regulatory status, the accurate answer is that neither has an approved use in men: clomiphene is approved only for female fertility, and enclomiphene isn’t an approved finished product at all.
Why supervision matters more than the choice itself
Across all of this, one thing keeps surfacing: the more important variable isn’t which compound gets picked, it’s whether the process is supervised by someone qualified to watch for problems and adjust course. Both are off-label for men. Both work the same way and both carry that visual side effect worth watching for [5]. And for both, the only legitimate path runs through a valid prescription and a licensed compounding pharmacy, since neither has an approved finished product to hand over at a counter.
FormBlends operates inside that framework. A prescriber reviews the person’s case, writes for whichever compound the bloodwork and goals support, and a state-licensed compounding pharmacy prepares the order. Both the full mixture and the isolated isomer move through the same oversight rather than two different standards. Naming this isn’t about declaring a winner between the two molecules. It’s about showing what supervised access looks like when neither one has an approved men’s-health product on the market, and it keeps the actual decision, which isomer fits a given man, where it belongs: with the clinician, not the shopper.
Worth restating plainly: compounded clomiphene and compounded enclomiphene are not FDA-approved finished drugs, and while the evidence for the class is consistent, it isn’t approval-grade.
The short version
Clomiphene and enclomiphene aren’t competitors. One is the whole molecule, the other is its faster-clearing active half, and they share a mechanism [5]. Their approval status isn’t symmetrical: clomiphene is FDA-approved for female fertility and used off-label in men, while enclomiphene, developed as Androxal, was never approved and exists only as a compounded product [1]. The best pooled evidence treats them as one class and finds a meaningful testosterone increase along with a fertility advantage over testosterone gel [4]. The idea that the isolated isomer causes fewer estrogen-related effects is reasonable, but unproven, the visual side effect applies to both [5], and what actually decides a good outcome is supervised, individualized care rather than a pick between two isomers.
Questions people tend to ask
Is enclomiphene just part of clomiphene? Yes. Clomiphene citrate is a mix of two mirror-image isomers, enclomiphene and zuclomiphene, so enclomiphene is simply one of the two pieces already present in every dose, separated and used alone [5]. Enclomiphene clears faster and is more active; zuclomiphene lingers longer and carries more estrogen-like character. Think of it as the full molecule versus its isolated active half, not two unrelated drugs.
Is enclomiphene approved and clomiphene not? It’s the reverse, at least for the part most people care about. Clomiphene is FDA-approved, but only for ovulatory dysfunction in women, so any use in men is off-label [1]. Enclomiphene was developed for men under the name Androxal, got a complete response letter in 2015, and was never approved. Today it only exists as a compounded, off-label product. Neither one has an approved men’s-health version available.
Does the research show enclomiphene beats clomiphene for testosterone? Not in any definitive, head-to-head way. The strongest evidence, a 2025 systematic review and meta-analysis, pooled both together as one SERM class and found total testosterone rose by roughly 274 ng/dL versus placebo, with better sperm parameters than testosterone gel [4]. No large trial has shown one clearly beating the other, so the class-level effect is what the evidence actually supports, not a declared winner.
Why do people think enclomiphene has fewer estrogen-related side effects? The logic is that removing zuclomiphene, the longer-lasting isomer with more estrogen-like activity, might reduce certain effects. It’s a sensible idea grounded in pharmacology, but it hasn’t been proven in solid comparative trials [4]. Worth raising with a prescriber, not worth treating as decided.
Do clomiphene and enclomiphene carry the same vision risk? Yes, both call for the same watchfulness. Clomiphene has documented visual disturbances, including blurred vision and shimmering spots, and the guidance is to stop and get an eye exam if they show up [5]. Since enclomiphene works through the same mechanism, it warrants the same attention, which is part of why supervision matters regardless of which one a person uses.
What is clomiphene actually used for in men? Off-label, it’s used to raise testosterone and LH without shutting down the body’s own hormone production the way testosterone injections can. Doctors reach for it most often in secondary hypogonadism, low sperm count tied to infertility, or as an option for men who want their testosterone up without giving up fertility. It’s not FDA-approved for any of this, so it comes down to a physician’s judgment.
What dose do men typically take? Most prescribers start somewhere between 12.5 and 25 mg every other day or daily, then adjust from there based on follow-up labs. Some go up to 50 mg daily, though higher doses tend to push estradiol up too, which can bring on side effects. There’s no single agreed-upon number, since the evidence base is still mostly smaller trials and case series, so checking labs along the way matters more than hitting a fixed target.
What side effects show up with clomiphene in men? The most commonly reported ones are mood changes, irritability, visual disturbances, and elevated estradiol, which can cause breast tenderness or gynecomastia. The visual symptoms, usually blurry or hazy vision, are a clear signal to stop and call a doctor right away. The mood-related effects seem tied in part to zuclomiphene’s estrogen-like activity in the brain. Not every man notices these, but they happen often enough that monitoring is standard.
Does clomiphene cause weight gain? There isn’t strong direct evidence that it does. Some men notice bloating or fluid retention, possibly linked to rising estrogen, but this isn’t well documented in the clinical literature. If testosterone climbs meaningfully, body composition can actually improve for some men over time. Anyone worried about weight is better served tracking estradiol alongside testosterone, since that gives a clearer read on what’s actually driving any change. Compounding pharmacies that work under physician supervision, FormBlends among them, can adjust isomer ratios to help manage estrogen-related effects when they come up.
References
- CLOMID (clomiphene citrate tablet), FDA-approved prescribing information, U.S. Food and Drug Administration (Drugs@FDA application 016131; DailyMed canonical label). Approved for the treatment of ovulatory dysfunction in women desiring pregnancy, with no approved male indication. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca373c1-4dba-4126-8616-5c533d606fe5
- Soares AH, et al. Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond). 2018;42(5):953-963. PMID: 29777228. Seventy-eight obese hypogonadal men, 50 mg clomiphene vs placebo for 12 weeks, with significant increases in total and free testosterone and in LH and FSH. https://pubmed.ncbi.nlm.nih.gov/29777228/
- Pelusi C, et al. Impact of clomiphene citrate on the steroid profile in dysmetabolic men with low testosterone levels. Horm Metab Res. 2021;53(8):520-528. PMID: 34384109. Randomized study showing clomiphene raised testosterone via pituitary stimulation rather than increased adrenal secretion.
- Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025. Pooled SERM vs placebo increase in total testosterone of about 273.76 ng/dL (95% CI 191.87 to 355.66), with favorable sperm parameters versus testosterone gel.
- Dadhich P, Hotaling JM, et al. Clomiphene. StatPearls. NCBI Bookshelf. SERM mechanism via hypothalamic estrogen-receptor antagonism increasing LH, FSH, and testosterone; clomiphene as a mixture of enclomiphene and zuclomiphene isomers; FDA approval centered on ovulation induction with male use described as off-label; documented visual adverse effects warranting discontinuation.
